Bausch & Lomb Opts Not To Negotiate With Visx For Technolas Eye Laser
This article was originally published in The Gray Sheet
Executive Summary
Bausch and Lomb has no plans to negotiate a patent licensing agreement with laser vision correction market leader Visx prior to introducing the Technolas 217 ophthalmic excimer laser in the U.S., company officials reported at a Feb. 24 teleconference announcing FDA approval.
You may also be interested in...
Visx v. B&L
Santa Clara, California eye laser manufacturer files suit in Delaware district court against Bausch & Lomb for infringement of its '388 patent on Sept. 19, the same day Visx received a reexamination certificate for the patent from the U.S. Patent and Trademark Office. The reissued patent covers 60 new claims and will expire in 2009. Since February, when B&L began marketing its Technolas 217 eye laser, the Rochester, New York company has denied the need to obtain rights under third-party patents (1"The Gray Sheet" Feb. 28, 2000, p. 3)
Visx v. B&L
Santa Clara, California eye laser manufacturer files suit in Delaware district court against Bausch & Lomb for infringement of its '388 patent on Sept. 19, the same day Visx received a reexamination certificate for the patent from the U.S. Patent and Trademark Office. The reissued patent covers 60 new claims and will expire in 2009. Since February, when B&L began marketing its Technolas 217 eye laser, the Rochester, New York company has denied the need to obtain rights under third-party patents (1"The Gray Sheet" Feb. 28, 2000, p. 3)
Alcon Entering Refractive Laser Surgery Market Via $890 Mil. Summit Buy
Alcon Labs' $890 mil. cash purchase of ophthalmic excimer laser manufacturer Summit Autonomous will place it on a level playing field with competitor Bausch & Lomb, which already competes in the eye laser market. The definitive deal was announced May 26.